安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Home - SOFIE
Another defining moment for SOFIE Biosciences! Last Friday, November 14, 2025, FAPI-GO, SOFIE’s [18F]FAPI-74 Phase 3 study in gastroesophageal cancers, officially went live!
- Who We Are - SOFIE
In 2006, the creation of SOFIE launched the aspiration of having a multifaceted approach to expand the reach of PET products for patients with advanced imaging needs This was further realized in 2017 with the addition of a radiopharmacy network with global distribution capabilities
- Careers - SOFIE
Transparency in Coverage (TiC) regulations requires health insurers and group Health Plans to post their provider link on company websites View SOFIE’s Link here View our Privacy Policy
- Find a Radiopharmacy - SOFIE
SOFIE is dedicated to providing reliable, high quality radiopharmaceuticals and cutting-edge technologies
- Pipeline Overview - SOFIE
In Nov 2019, SOFIE Biosciences (SOFIE) licensed quinoline-based PET tracers, developed by the team at Heidelberg University, that act as FAP inhibitors (FAPI) and showed promising clinical data in a variety of oncologic and non oncologic diseases
- News - SOFIE
SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies, following successful FDA engagement 1, Oct 2025 FAPI Symposium at SNMMI Hits its Mark 22, Jun 2025 SOFIE Biosciences opens PET Manufacturing Facility, expanding service in Illinois, Missouri, and Indiana 1, Apr 2025 SOFIE network expands production of 18F-FAPI-74 15, Jan
- Network - SOFIE
SOFIE has built a high-capacity PET radiopharmaceutical network capable of delivering large volumes of products to as many patients as possible Our product lines include FDG, Pylarify, Neuraceq, and other clinical trial products
- Team - SOFIE
Our team works alongside our Pharma and Academic partners to revolutionize clinical diagnostics and therapeutics to better understand and treat the biology of disease
|
|
|